26.97
2.71 (11.17%)
| Previous Close | 24.26 |
| Open | 24.95 |
| Volume | 912,989 |
| Avg. Volume (3M) | 846,525 |
| Market Cap | 2,092,659,584 |
| Price / Sales | 650.22 |
| Price / Book | 8.29 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Diluted EPS (TTM) | -3.06 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 8.06 |
| Operating Cash Flow (TTM) | -169.86 M |
| Levered Free Cash Flow (TTM) | -68.57 M |
| Return on Assets (TTM) | -25.34% |
| Return on Equity (TTM) | -65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Spyre Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | 3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.80 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.71% |
| % Held by Institutions | 106.07% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (BTIG, 159.55%) | Buy |
| Median | 64.00 (137.30%) | |
| Low | 53.00 (Mizuho, 96.52%) | Buy |
| Average | 62.75 (132.67%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 32.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 16 Jan 2026 | 70.00 (159.55%) | Buy | 33.24 |
| Mizuho | 18 Dec 2025 | 53.00 (96.51%) | Buy | 33.47 |
| Citigroup | 17 Dec 2025 | 64.00 (137.30%) | Buy | 33.06 |
| Jones Trading | 01 Dec 2025 | 64.00 (137.30%) | Buy | 28.66 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jan 2026 | Announcement | Spyre Therapeutics Announces Grants of Inducement Awards |
| 12 Jan 2026 | Announcement | Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 |
| 08 Jan 2026 | Announcement | Spyre Therapeutics Announces Grants of Inducement Awards |
| 05 Dec 2025 | Announcement | Spyre Therapeutics Announces Grants of Inducement Awards |
| 07 Nov 2025 | Announcement | Spyre Therapeutics Announces Grants of Inducement Awards |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |